RightFit
RecruitingPhase not listed

FTT PET/CT in Metastatic Prostate Cancer

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
Male only
Healthy volunteers
Not stated
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: CT scans, Biopsies, Injections

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer."
  • "Tissue from a clinical or research biopsy will be compared to imaging measures, if available."
  • "After injection of \[18F\]FTT patients will undergo a skull base to mid-thigh scan, starting at approximately 60 minutes post injection."
  • "PET/CT imaging sessions will include an injection of 12 mCi of \[18F\]FTT intravenously (approximate range for most studies is anticipated to be 8-12 mCi ). of \[18F\] FTT."
  • "All evaluable patients may start new therapy following the \[18F\]FTT PET/CT scan."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study uses FTT PET/CT scans to look at the activity of PARP, a protein, in prostate cancer that has spread to other parts of the body. Up to 30 men will have a scan before starting a new treatment and may choose to have a second scan 1–21 days after treatment starts. If tissue from a biopsy is available, it will be compared with the scan results.

Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be at least 18 years old.
  • Have prostate cancer confirmed by a tissue sample.
  • Have cancer that has spread, with at least one cancer spot seen on a standard scan.
  • Be considered for a new treatment or a treatment change using drugs that block PARP, hormone-lowering treatment, and/or chemotherapy, with or without other drugs.
  • Understand that this is a research study and agree in writing to take part before any study procedures.

Who can't join

  • A study doctor or treating doctor thinks you cannot tolerate the scans.
  • A study doctor thinks a current health condition could make the study unsafe for you or keep you from taking part successfully.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: 1. Participants will be ≥ 18 years of age 2. Histologically proven prostate carcinoma 3. Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET/CT, Ultrasound) 4. Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and/or androgen deprivation therapy (ADT) and/or chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care. 5. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: 1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician 2. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

Study sites (1)

PA